10月2日，麦克森药物批发盘中上涨4.52%，报892.38美元/股，成交额3.48亿美元。
消息面上，CVS Health旗下Aetna宣布自9月1日起在符合条件的Medicaid州将事前授权捆绑方案扩展至所有癌症类型，并计划于下一财年将该举措推广至全业务线。此举有望直接利好麦克森旗下肿瘤及多专科业务板块的处方技术解决方案需求。与此同时，公司此前宣布的22.5亿美元收购精准医疗集团交易持续推进，该标的将并入肿瘤及多专科业务板块，有助于拓展临床研究与药物商业化服务能力。
保健护理产品经销商板块整体表现强势，同行卡地纳健康上涨3.22%、Cencora上涨2.34%，行业联动效应显著。麦克森公司是一家多元化医疗保健服务领导者，致力于与生物制药公司、医疗服务提供者、药房及政府等合作，提升优质医疗服务的可及性与可负担性。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.